Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules
Open Access
- 29 April 2026
- journal article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 49 (3) , 136-142
Abstract
Objective: Both a catechol-O-methyltransferase inhibitor and extended-release (ER) levodopa formulations may enhance levodopa treatment through a more continuous levodopa delivery to the striatum; the combination of these therapies has not undergone a pharmacokinetic study. We evaluated the effects of once-daily opicapone 50 mg on levodopa plasma pharmacokinetics when added to a carbidopa/levodopa (CD/LD)-ER formulation (RYTARY ® ). Materials and Methods: This was an exploratory, open-label study of levodopa’s pharmacokinetics measured over 24 hours in healthy adults. Enrolled individuals received CD/LD-ER three times daily (TID) alone for 3 days, followed by once-daily opicapone for 14 days. On the last 3 days of the opicapone regimen, participants received CD/LD ER TID again. Pharmacokinetic parameters were evaluated after the 3-day exposure to CD/LD-ER alone and with concomitant administration of opicapone. Results: Eighteen healthy adults (9 male, 9 female) entered and completed the study. Levodopa exposure (area under the time-concentration curve) was higher with opicapone than with CD/LD-ER alone across all dosing intervals, including between 21:00 and 07:00 (10801.5 vs. 5153.3 ng/mL·h). Over 24 hours, mean levodopa trough concentration (C trough ) was higher with opicapone versus CD/LD-ER alone (677.2 vs. 266.8 ng/mL), as was minimum C trough (302.9 vs. 41.3 ng/mL). There was a greater increase in C trough (208%) than in maximum plasma concentration (75%), decreasing the fluctuation index by 38%. Conclusions: Adding opicapone to CD/LD-ER enhanced levodopa pharmacokinetics in healthy adults, by increasing levodopa trough levels. Notably, opicapone increased overnight and morning levodopa concentrations and decreased daily levodopa concentrations, sub-therapeutic for Parkinson disease patients.Keywords
This publication has 32 references indexed in Scilit:
- The frequency and nature of sleep disorders in a community‐based population of patients with Parkinson’s diseaseEuropean Journal of Neurology, 2007
- The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerationsExpert Opinion on Pharmacotherapy, 2006
- Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s diseaseJournal of Neural Transmission, 2006
- Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be consideredJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Sleep disorders in Parkinson's diseaseMovement Disorders, 2002
- The Effects of Different Repeated Doses of Entacapone on the Pharmacokinetics of L-Dopa and on the Clinical Response to L-Dopa in Parkinson's DiseaseClinical Neuropharmacology, 2001
- Acute Effects of COMT Inhibition on L-DOPA Pharmacokinetics in Patients Treated with Carbidopa and SelegilineClinical Neuropharmacology, 1995
- Effects of tolcapone in Parkinson's patients taking L‐dihydroxyphenylalanine/carbidopa and selegilineMovement Disorders, 1995
- Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patientsNeurology, 1994
- Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobilityNeurology, 1988